Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects:
5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28
8 of 12 (67%) subjects achieved > 50% reduction in UPCR (6 subjects still dosing)
Itolizumab continues to demonstrate favorable safety and tolerability through six months of treatment
Management will host a conference call and webcast today at 8:00 am ET
Management will host a conference call accompanied by a slide presentation to discuss the interim data from the Type B portion of the EQUALISE study in patients with lupus nephritis, for analysts and institutional investors, at 8:00 am ET today, September 27, 2022. To access the call, please dial (888) 350-3846 or (646) 960-0251 and, if needed, provide confirmation number 8770084. A live webcast of the call will also be available on the company’s Investor Relations page at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx. The webcast will be archived for 180 days.
https://finance.yahoo.com/news/equillium-announces-positive-interim-results-110000997.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.